TransEnterix (TRXC) Misses Q1 EPS by 1c, Revenues Miss
Get Alerts TRXC Hot Sheet
Join SI Premium – FREE
TransEnterix (NYSE: TRXC) reported Q1 EPS of ($0.09), $0.01 worse than the analyst estimate of ($0.08). Revenue for the quarter came in at $2.2 million versus the consensus estimate of $5.81 million.
- Total revenue of $2.2 million in the first quarter of 2019
- Sold one Senhance System globally in the first quarter in 2019
- Received U.S. FDA clearance for Senhance Ultrasonic System
“Commercially, we were disappointed with our results in the first quarter. We did however make solid progress towards the expansion of our global sales infrastructure and the development of our U.S. installed base to support future growth,” said Todd M. Pope, President and CEO of TransEnterix. “As we look to the balance of 2019, we will continue to leverage the commercial foundation we have built globally to drive the adoption of Senhance both in the U.S. and abroad. We remain confident in the quality of the global pipeline and expect to show meaningful revenue growth in the second half of the year.”
For earnings history and earnings-related data on TransEnterix (TRXC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Bitmine reports 5.82 million ETH holdings, $11.4B total assets
- BitFuFu Inc. (FUFU) Misses Q2 EPS by 13c
Create E-mail Alert Related Categories
Corporate News, Earnings, Management CommentsRelated Entities
Earnings, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share